Patients with multiple sclerosis (MS) are missing out on vital drugs that can put the disease on pause, because there is a nationwide shortage of specialists able to prescribe them.
Nine in ten of those with the incurable neurological disease can’t access a drug that can halt progression by up to four years, according to NHS data seen by the MS Society.
Just a third can get the only other medicine that benefits this group of patients, who are in the later stages of the disabling illness.
